In contrast to hemodialysis, peritoneal dialysis can be carried out by patients themselves, thus increasing their mobility and independence. However, infections and chronic inflammation often results from this type of treatment, leading to a termination of the treatment in most cases. Zytoprotec promises to counteract this damaging mechanism thanks to its dialysis solution PD-protec, which also improves the effectiveness of the peritoneal dialysis. The active agent alanyl-glutamine is currently being tested in a Phase II clinical study, the results of which are expected to be available in the fall of 2016. According to the business plan of the company, the project or the company is expected to be sold in the course of the year 2017, comprising an exit for the investors.